Back
to home » Treatment News » Top Stories
 October 30, 2008
|
ICAAC 2008: Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studies
More than 10 years after combination HIV treatment was heralded as the one and only way to treat HIV, data continue to emerge suggesting that monotherapy—the use of just one HIV drug—may be a possibility. Long-term results from two Kaletra (lopinavir/ritonavir) studies, reported at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA), continue to show that there may be potential for two monotherapy approaches.
|
|
|
October 29, 2008
|
EMD Serono Buys Rights to Sell Tesamorelin in U.S.
Theratechnologies announced today that it has sold the rights to sell the experimental lipodystrophy drug tesamorelin in the United States—if the drug is approved by the U.S. Food and Drug Administration—to EMD Serono.
|
|
|
ICAAC 2008: Has HIV Evolved to Become More Dangerous?
Twenty-five years into the HIV epidemic, has the virus evolved to become more dangerous? This was the question asked by a research team headed by Nancy Crum-Cianflone, MD, of the TriService AIDS Clinical Consortium at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA) in Washington, DC.
|
|
|
October 28, 2008
|
ICAAC 2008: PRO 140 Has Long-Lasting Activity Against HIV
Positive early results from a Phase II clinical trial of intravenous (IV) PRO 140, an experimental HIV entry inhibitor, were reported October 26 at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA). Separately, Progenics Pharmaceuticals announced this week encouraging results from a study evaluating a much more user-friendly subcutaneous (SC) formulation of PRO 140.
|
|
|
ICAAC 2008: New NNRTI Called RDEA806 Shows Promise
Once-daily RDEA806, an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Ardea Biosciences, appears highly active against HIV, is unlikely to have significant interactions with other meds and may have a useful side effect—reducing uric acid levels.
|
|
|
October 27, 2008
|
ICAAC 2008: Isentress Comparable to Sustiva for First-Time Treatment
Isentress (raltegravir) appears to work just as well as Sustiva (efavirenz), with fewer drug-related side effects, in HIV-positive patients starting antiretroviral (ARV) therapy for the first time, according to a 48-week Phase III study analysis reported yesterday at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA).
|
|
|
ICAAC 2008: Selzentry Reanalysis Shows Potential as First-Line Treatment
Selzentry (Celsentri; maraviroc) is comparable to Sustiva (efavirenz) in HIV-positive patients starting antiretroviral (ARV) treatment for the first time, according to a new analysis of a study that originally suggested that Selzentry was less effective than the standard-of-care non-nucleoside reverse transcriptase inhibitor (NNRTI).
|
|
|
ICAAC 2008: Should ARV Treatment Be Started When CD4s Fall Below 500?
New research from a team of U.S. and Canadian researchers suggests that HIV-positive people have less risk of dying if they start antiretroviral (ARV) therapy sooner than is currently recommended, according to a presentation on Sunday, October 26, at the 2008 joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA).
|
|
|
| October 24, 2008
|
October 23, 2008
|
'Undetectable = Noninfectious' Debate Continues at U.K. Conference
Experts at a U.K. conference confirmed that effective antiretroviral (ARV) therapy “significantly reduces” the risk of HIV transmission. However, according to a report from aidsmap, researchers and community leaders at the gathering avoided speaking in absolute terms. For example, they did not say that risk of spreading the virus is nonexistent in HIV-positive people with undetectable viral loads and no other sexually transmitted infections (STIs). They also pointed out that important questions remain unanswered.
|
|
|
October 22, 2008
|
Prezista Approved for First-Time Treatment Takers
The U.S. Food and Drug Administration (FDA) has approved the protease inhibitor Prezista (darunavir) for HIV-positive people beginning antiretroviral treatment for the first time, the drug’s manufacturer, Tibotec Therapeutics, announced today. Prezista must be combined with Norvir, but can be taken once a day by HIV-positive people who have not used other ARVs in the past.
|
|
|
| October 21, 2008
|
October 20, 2008
|
Norvir and Viral Hepatitis Increase HIV Drug levels, Risk of Side Effects
The ability of Norvir to boost the blood levels of other antiretroviral (ARV) drugs is amplified in HIV-positive people who are also infected with either hepatitis B or hepatitis C , according to a study published online in the Journal of Acquired Immune Deficiency Syndromes. As a result, researchers warn, people coinfected with HIV and hepatitis may be at an increased risk for ARV side effects.
|
|
|
October 17, 2008
|
50% of MRSA Skin Infections Return Within 1 Year
Half of HIV-positive patients with skin infections caused by drug-resistant staph had a recurrence of the infection within one year, according to a research letter in the October 1 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
| October 16, 2008
|
October 15, 2008
|
Third Dose of Hep A Vaccine May Increase Immunity
An additional third booster shot of the hepatitis A virus (HAV) vaccine increased the chance of an HIV-positive person acquiring immunity to HAV and increased the number of antibodies against HAV after one year, according to the authors of a study published online in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
October 14, 2008
|
Menopause, Tenofovir and Didanosine Increase Bone Loss
Working out with weights and maintaining high albumin levels protected against bone loss, while completing menopause or taking tenofovir (found in Viread, Truvada and Atripla) or didanosine (Videx) led to bone loss in HIV-positive patients, according to a study published online October 3 in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
October 13, 2008
|
New Anti-HIV Drug Target Discovered
Scientists at the University of Southern California at Los Angeles (USC) have uncovered the atomic structure of our bodies’ natural built-in antiviral factor, called APOBEC-3G.
|
|
|
October 10, 2008
|
Single Dose of Diflucan Good for Thrush
A single 750 milligram dose of Diflucan (fluconazole) is as safe and effective as taking 150 mg of Diflucan once daily for 14 days in curing oral candidiasis, also known as thrush, according to a study in the October 7 issue of Clinical Infectious Diseases.
|
|
|
October 09, 2008
|
Strength Training Burns More Fat Than Endurance Exercise in HIV
Strength training—which primarily involves lifting weights—leads to greater loss of total body fat than endurance training—including activities such as running and biking—in people living with HIV, according to a study published in the October issue of The Journal of Clinical Endocrinology & Metabolism.
|
|
|
October 08, 2008
|
Circumcision May Not Prevent HIV in MSM
While African trials have shown that circumcision lowers the risk of female to male HIV transmission by 60 percent, a U.S.-based study has recently found that HIV prevalence among circumcised men who have sex with men (MSM) is not significantly lower than their uncircumcised counterparts, BBC News reports.
|
|
|
Merck Testing Once-Daily Isentress
Merck has announced that it is launching a clinical trial to evaluate whether its integrase inhibitor, Isentress (raltegravir), can be used once daily by people who’ve never taken antiretroviral (ARV) therapy.
|
|
|
| October 07, 2008
|
October 06, 2008
|
Pneumonia Hospitalizations Still High for Positive Patients
Although hospitalizations for bacterial pneumonia have greatly decreased among people living with HIV in Denmark since the introduction of combination antiretroviral (ARV) therapy in 1996, they remain six times higher than in the general population, according to a study published online October 3 in Clinical Infectious Diseases.
|
|
|
October 03, 2008
|
Tenofovir Linked to Mild Decrease in Kidney Function, but Not Kidney Disease
People taking a regimen that contains tenofovir (found in Viread, Truvada and Atripla) were more likely to experience mild decreases in kidney function over 144 weeks of treatment than people taking other antiretrovirals (ARV), but they were no more likely to have serious kidney problems, according to a study published in the October 18 issue of AIDS.
|
|
|
| October 02, 2008
|
October 01, 2008
|
Delayed-Release Videx (EC) Now OK for Some Kids
Videx EC, the delayed-release form of Videx, may now be taken by children who weigh at least 44 pounds, according to an update to the drug’s prescribing information from the United States Food and Drug Administration (FDA).
|
|
|
|
|
|
 |
|
